Program
AZD4954
A development code. Also written as “[14C]AZD4954 Oral Solution”, “AZD4954 film-coated tablet” and “[14C]AZD4954 Solution for Infusion”.
Its studies are mostly in Dyslipidemias, led by AstraZeneca.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 32 open or running | phase 1since May 19, 2025 | May 19, 2025 | Mar 17, 2027phase 1 · NCT07812077 |
- Named in AstraZeneca’s own pipeline as
AZD4954
, phase 1, as of Oct 30, 2026 (source).
Also a collaborator on its studies: quotient-sciences.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 19, 2025First study: phase 1 study in DyslipidemiasFirst studyNCT06980428 · 171 planned · United States
- Mar 31, 2026Phase 1 study in DyslipidemiasNCT07513571 · 31 enrolled · United States
- Sep 4, 2026Phase 1 study in Healthy ParticipantsNCT07812077 · 16 planned · United Kingdom
- Nov 13, 2026Primary completion moved from 2026-12-17 to 2027-03-17Date moved laterphase 1 · +3 months · NCT07812077
Ahead
- Mar 17, 2027Primary completion: phase 1 study in Healthy ParticipantsNCT07812077
- Apr 9, 2027Primary completion: phase 1 study in DyslipidemiasNCT06980428
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07812077Healthy Participants · United Kingdom | 1 | Recruiting | Mar 17, 2027 | 16 |
| NCT07513571Dyslipidemias · United States | 1 | Completed | Jul 8, 2026 | 31 |
| NCT06980428Dyslipidemias · United States | 1 | Recruiting | Apr 9, 2027 | 171 |
How it is read
Names in the registry
- “AZD4954”, 2 entries
- “[14C]AZD4954 Oral Solution”, 1 entry
- “AZD4954 film-coated tablet”, 1 entry
- “[14C]AZD4954 Solution for Infusion”, 1 entry
Codes read as this program: AZD4954.
Conditions, from the studies’ own filings
- Dyslipidemias, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.